Outsourcing

Sterling Pharma Signs Agreement to Support COVID-19 Treatment Development

July 29, 2020

Sterling Pharma Solutions has signed a deal with Moleculin Biotech to support the development of WP1122, a potential COVID-19 treatment.

Novavax and Fujifilm Diosynth Biotechnologies Begin Manufacturing of COVID-19 Vaccine Candidate

July 23, 2020

Fujifilm Diosynth Biotechnologies’ North Carolina site will be used to manufacture Novavax’ NVX‑CoV2373 vaccine candidate for a Phase III clinical trial.

Catalent Invests Millions to Create European Clinical Manufacturing Center of Excellence

July 21, 2020

Catalent has unveiled investment plans to create a European center of excellence for clinical biologics formulation development and drug product fill/finish services.

Catalent Invests Millions to Create European Clinical Manufacturing Center of Excellence

July 21, 2020

Catalent has unveiled plans to invest in a European center of excellence for clinical biologics formulation development and drug product fill/finish services at its facility in Limoges, France.

Vetter Expands Fill/Finish Capacity with Acquisition of New Site in Austria

July 08, 2020

The acquisition will give the CDMO additional clinical filling options in Europe, which is expected to come online in 2021.

Grand River Aseptic Manufacturing Opens Large-Scale Injectable Fill/Finish Facility

July 02, 2020

The new facility in Grand Rapids, MI, is part of the CDMO’s aggressive expansion plan.

Contractors Balance Increased Demand During COVID-19

July 01, 2020

The COVID-19 pandemic has created a rise in demand for R&D and a shift in focus for some contract organizations.

Sartorius Stedim Biotech Launches Consultancy Services for Viral Clearance Validation

June 30, 2020

The company now offers its CONFIDENCE virus clearance services to support validation of viral clearance processes.

Cobra Biologics to Manufacture AstraZeneca’s COVID-19 Vaccine Candidate

June 17, 2020

Cobra Biologics has signed a supply agreement to provide GMP manufacturing for AstraZeneca’s AZD1222 COVID-19 vaccine candidate.

Novavax Contracts to Expand Adjuvant Production

June 04, 2020

Agreements with the PolyPeptide Group and AGC Biologics will scale up production of the Novavax Matrix-M adjuvant.